

Title (en)
TELOMERASE-SPECIFIC CANCER VACCINE

Title (de)
TELOMERASE-SPEZIFISCHES KREBSIMPFSTOFF

Title (fr)
VACCIN ANTICANCEREUX SPECIFIQUE DE LA TELOMERASE

Publication
EP 1171612 A2 20020116 (EN)

Application
EP 00920996 A 20000407

Priority
• IB 0000610 W 20000407
• US 12853999 P 19990409

Abstract (en)
[origin: WO0061766A2] Telomerase-specific T-cell antigens are provided, which are useful in generating T-cell responses against telomerase. Formulations of telomerase antigens as vaccines are useful in treating and preventing cancer, using in vivo or ex vivo techniques.

IPC 1-7
C12N 15/54; **C12N 9/12**; **A61K 38/45**; **A61K 9/127**; **C12N 5/08**; **A23L 1/00**

IPC 8 full level
C12N 15/09 (2006.01); **A61K 9/127** (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61P 35/00** (2006.01); **C07K 7/06** (2006.01); **C07K 7/08** (2006.01); **C12N 5/08** (2006.01); **C12N 5/10** (2006.01); **C12N 9/12** (2006.01); **C12N 15/54** (2006.01)

CPC (source: EP)
A61K 39/461 (2023.05); **A61K 39/4622** (2023.05); **A61K 39/464457** (2023.05); **A61P 35/00** (2017.12); **C12N 9/1241** (2013.01); **C12Y 207/07049** (2013.01); **A61K 39/00** (2013.01)

Citation (search report)
See references of WO 0061766A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0061766 A2 20001019; **WO 0061766 A3 20010308**; AU 4139400 A 20001114; AU 781376 B2 20050519; CA 2368967 A1 20001019; EP 1171612 A2 20020116; JP 2002541811 A 20021210

DOCDB simple family (application)
IB 0000610 W 20000407; AU 4139400 A 20000407; CA 2368967 A 20000407; EP 00920996 A 20000407; JP 2000611689 A 20000407